Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Prevymis (letermovir by Year
Prevymis (letermovir — CMV prophylaxis) — Worldwide reported growth YoY (%) (%)
Merck Prevymis (letermovir: 25.0% in FY2025, down 5.0 pts from a year earlier.
Latest, FY2025
25.0%
Period ended Dec 31, 2025
Change on a year earlier
-5.0 pts
30.0% in FY2024
History
5 years
Since FY2020
Sources
5
Documents cited below
Where the FY2025 figure comes from
“|| Prevymis | 978 | 785 | 25 | 475 | 371 | 28 | 503 | 414 | 21”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 8-K Table 3 / 3a / 3b Product Sales.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Prevymis (letermovir — CMV prophylaxis) — Worldwide reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 25.0% | -5.0 pts | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 30.0% | -11.0 pts | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 41.0% | – | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2021 | Dec 31, 2021 | 32.0% | -38.0 pts | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2020 | Dec 31, 2020 | 70.0% | – | Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗ |
Cite this data
StockData. (2026). Merck Prevymis (letermovir (%), annual FY2020–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-prevymis-ww-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.